Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
Cureus ; 13(8): e17152, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34548969

RESUMO

Coronavirus disease 2019 (COVID-19) is currently a significant cause of acute respiratory failure worldwide, leading to irreversible fibrotic lung disease. In patients with persistent respiratory failure after acute COVID-19 infection, lung transplant is an emerging option. Here, we have presented a case where the patient required venovenous extracorporeal membrane oxygenation (VV-ECMO) support for 33 days until a bilateral lung transplant was performed on day 71 after the initial COVID-19 infection. The early outcomes have been favorable. Currently, no guidelines exist for an acceptable time period after initial COVID-19 infection, duration of negative COVID polymerase chain reaction (PCR) testing, or negative Vero cell culture in the setting of persistent positive COVID PCR testing before listing for a lung transplant. Due to a lack of standardized guidelines, this patient was not listed for a lung transplant until the COVID-19 PCRs came negative on days 47 and 49 after the infection.

2.
BMJ Case Rep ; 14(5)2021 May 24.
Artigo em Inglês | MEDLINE | ID: mdl-34031090

RESUMO

A 52-year-old woman with cystic fibrosis presented to the emergency department with expressive aphasia and right-sided hemiparesis. CT scan of the brain revealed a left middle cerebral artery territory infarct. A diagnosis of cerebral paradoxical embolisation associated with patent foramen ovale and a history of deep venous thrombosis was made. The patient underwent endovascular thrombectomy and percutaneous closure of patent foramen ovale. Current literature, including five published case reports, pertaining to the subject is discussed. The unique aspects of the case are highlighted, including the particular risk of cerebral paradoxical embolisation in patients with cystic fibrosis. The result of this case report, in context to previously reported literature, suggests that clinicians should be aware of paradoxical embolisation in patients with cystic fibrosis via an intracardiac shunt, particularly with implanted vascular access devices and a history of deep venous thrombosis.


Assuntos
Fibrose Cística , Embolia Paradoxal , Forame Oval Patente , Encéfalo , Fibrose Cística/complicações , Embolia Paradoxal/etiologia , Feminino , Forame Oval Patente/complicações , Forame Oval Patente/diagnóstico por imagem , Humanos , Pessoa de Meia-Idade , Trombectomia
3.
Front Immunol ; 12: 574425, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33643308

RESUMO

The rapid advancement of the COVID-19 pandemic has prompted an accelerated pursuit to identify effective therapeutics. Stages of the disease course have been defined by viral burden, lung pathology, and progression through phases of the immune response. Immunological factors including inflammatory cell infiltration and cytokine storm have been associated with severe disease and death. Many immunomodulatory therapies for COVID-19 are currently being investigated, and preliminary results support the premise of targeting the immune response. However, because suppressing immune mechanisms could also impact the clearance of the virus in the early stages of infection, therapeutic success is likely to depend on timing with respect to the disease course. Azithromycin is an immunomodulatory drug that has been shown to have antiviral effects and potential benefit in patients with COVID-19. Multiple immunomodulatory effects have been defined for azithromycin which could provide efficacy during the late stages of the disease, including inhibition of pro-inflammatory cytokine production, inhibition of neutrophil influx, induction of regulatory functions of macrophages, and alterations in autophagy. Here we review the published evidence of these mechanisms along with the current clinical use of azithromycin as an immunomodulatory therapeutic. We then discuss the potential impact of azithromycin on the immune response to COVID-19, as well as caution against immunosuppressive and off-target effects including cardiotoxicity in these patients. While azithromycin has the potential to contribute efficacy, its impact on the COVID-19 immune response requires additional characterization so as to better define its role in individualized therapy.


Assuntos
Azitromicina/uso terapêutico , Tratamento Farmacológico da COVID-19 , Inflamação/tratamento farmacológico , Neutrófilos/imunologia , Citocinas/metabolismo , Humanos , Imunomodulação , Pandemias , SARS-CoV-2
4.
Prog Transplant ; 29(3): 220-224, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31159656

RESUMO

INTRODUCTION: Since the largest study on extensively drug-resistant organisms and lung transplantation in patients with cystic fibrosis, there have been innovations and advancements in the treatment of Pseudomonas aeruginosa. RESEARCH QUESTION: What differences exist for patients with cystic fibrosis with a history of extensively drug-resistant infections who undergo lung transplantation despite treatment advances with antimicrobial therapy? STUDY DESIGN: Two-center, retrospective, cohort study conducted in 44 patients with cystic fibrosis chronically infected with extensively drug-resistant organisms who received a lung transplant from January 2008 through August 2016. Patients in the resistant cohort were chronically infected with pan-resistant P aeruginosa, polymyxin-sensitive only, or sensitive to 2 antibiotic classes (polymyxin plus one other); remaining patients with more susceptible P aeruginosa or no P aeruginosa remained in the control cohort. The primary outcome is a composite of patient survival, retransplantation, chronic lung allograft dysfunction, and acute rejection 12 months posttransplant. Categorical variables were analyzed using χ2 testing. The independent samples t test was utilized for continuous variables. RESULTS: There was no difference in the primary outcome (40% vs 37%, P = .831). Differences between patient survival (84% vs 95%, P = .487), the incidence of acute rejection (20% vs 33%, P = .323), and the incidence of chronic lung allograft rejection (12% vs 5%, P = .441) were not different between groups. DISCUSSION: Recipients chronically infected with an extensively resistant P aeruginosa had similar outcomes compared to those infected with more sensitive organisms.


Assuntos
Antibacterianos/uso terapêutico , Fibrose Cística/cirurgia , Farmacorresistência Bacteriana Múltipla , Rejeição de Enxerto/epidemiologia , Infecções por Pseudomonas/terapia , Pseudomonas aeruginosa/fisiologia , Taxa de Sobrevida , Adolescente , Adulto , Estudos de Casos e Controles , Doença Crônica , Fibrose Cística/complicações , Feminino , Humanos , Pneumopatias/epidemiologia , Transplante de Pulmão , Masculino , Polimixinas/uso terapêutico , Prognóstico , Infecções por Pseudomonas/complicações , Infecções por Pseudomonas/microbiologia , Reoperação/estatística & dados numéricos , Estudos Retrospectivos , Adulto Jovem
5.
Bioorg Med Chem Lett ; 26(4): 1305-9, 2016 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-26826023

RESUMO

Pseudomonas aeruginosa is a common biofilm-forming bacterial pathogen implicated in diseases of the lungs. The extracellular polymeric substances (EPS) of respiratory Pseudomonas biofilms are largely comprised of anionic molecules such as rhamnolipids and alginate that promote a mucoid phenotype. In this Letter, we examine the ability of negatively-charged fluoroquinolones to transverse the EPS and inhibit the growth of mucoid P. aeruginosa. Anionic fluoroquinolones were further compared with standard antibiotics via a novel microdiffusion assay to evaluate drug penetration through pseudomonal alginate and respiratory mucus from a patient with cystic fibrosis.


Assuntos
Antibacterianos/química , Fluoroquinolonas/química , Pseudomonas aeruginosa/fisiologia , Ânions/química , Antibacterianos/síntese química , Antibacterianos/farmacologia , Biofilmes/efeitos dos fármacos , Fluoroquinolonas/síntese química , Fluoroquinolonas/farmacologia , Testes de Sensibilidade Microbiana
6.
Pharmacotherapy ; 36(1): 13-8, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26748559

RESUMO

STUDY OBJECTIVE: To evaluate the pharmacokinetics and pharmacodynamics of ceftaroline in adults with cystic fibrosis (CF). DESIGN: Open-label, single-center, prospective study. SETTING: University-affiliated teaching institution. PATIENTS: Eight patients with a diagnosis of CF and a history of methicillin-resistant Staphylococcus aureus who were treated with ceftaroline between November 2013 and September 2014. INTERVENTION: All patients received at least three doses of intravenous ceftaroline 600 mg every 12 hours, administered as a 60-minute infusion, to achieve steady-state concentrations before blood sample collection. After an interim analysis of the first four patients' pharmacokinetic data, the remaining four patients received a change in dosage of ceftaroline to 600 mg every 8 hours. MEASUREMENTS AND MAIN RESULTS: Patients' blood samples were collected at two time points, 2 and 6 hours after infusion initiation, after administration of at least three doses of ceftaroline. Serum ceftaroline concentrations were determined by using a validated mass spectrometry, with a lower limit of detection of 20 ng/ml. These ceftaroline concentrations were used to estimate patient-specific pharmacokinetic parameters, and 10,000-patient Monte Carlo simulations were performed to determine the pharmacodynamic probability of target attainment (PTA) for ceftaroline in adults with CF. A PTA of 90% or higher for the desired pharmacodynamic target was considered adequate. The PTA for 60% or higher of the dosing interval during which free (unbound) drug concentrations exceed the minimum inhibitory concentration (%fT > MIC) was simulated for various MICs. Compared with values previously reported in other populations, the volume of distribution was increased in the study patients, and the estimated half-life was shorter. Monte Carlo simulations revealed that a dose of ceftaroline 600 mg every 8 hours, infused over 60 minutes, maintained a higher than 90% PTA for %fT > MIC of 60% or higher for an MIC at the susceptibility breakpoint of 1 mg/L. CONCLUSION: The pharmacokinetics of ceftaroline is altered in adults with CF, which suggests the need for modified dosing in this patient population to achieve adequate %fT > MIC. A dosage of intravenous ceftaroline 600 mg every 8 hours administered as a 60-minute infusion should be considered to achieve 60% fT > MIC.


Assuntos
Antibacterianos/farmacocinética , Cefalosporinas/farmacocinética , Fibrose Cística/complicações , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/sangue , Antibacterianos/uso terapêutico , Cefalosporinas/administração & dosagem , Cefalosporinas/sangue , Cefalosporinas/uso terapêutico , Fibrose Cística/metabolismo , Esquema de Medicação , Feminino , Humanos , Infusões Intravenosas , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Estudos Prospectivos , Adulto Jovem , Ceftarolina
7.
J Cyst Fibros ; 13(2): 164-71, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24018177

RESUMO

BACKGROUND: Azithromycin treatment improves clinical parameters in patients with CF, and alters macrophage activation from a pro-inflammatory (M1) phenotype to a pro-fibrotic, alternatively activated (M2) phenotype. The transcriptional profile of cells from patients receiving azithromycin is unknown. METHODS: Gene expression in association with macrophage polarization, inflammation, and tissue remodeling was assessed from sputum samples collected from patients with CF. Transcriptional profiles and clinical characteristics, including azithromycin therapy, were compared. RESULTS: Expression of NOS2 and TNFα was decreased in subjects receiving azithromycin, whereas expression of M2-associated genes was unaffected. Principal component analysis revealed gene expression profiles consistent with M1- (MMP9, NOS2, and TLR4) or M2-polarization (CCL18, fibronectin, and MR1) in select subject groups. These expression signatures did not significantly correlate with clinical characteristics. CONCLUSIONS: Pro-inflammatory gene expression was low in subjects receiving AZM. Genes were stratified into groupings characteristic of M1- or M2-polarization, suggesting that overall polarization status is distinct among patient groups.


Assuntos
Azitromicina , Fibrose Cística , Expressão Gênica/efeitos dos fármacos , Inflamação , Macrófagos Alveolares , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Azitromicina/administração & dosagem , Azitromicina/efeitos adversos , Criança , Fibrose Cística/diagnóstico , Fibrose Cística/tratamento farmacológico , Fibrose Cística/metabolismo , Fibrose Cística/fisiopatologia , Feminino , Perfilação da Expressão Gênica , Estudo de Associação Genômica Ampla , Humanos , Inflamação/metabolismo , Inflamação/patologia , Inflamação/fisiopatologia , Mediadores da Inflamação/metabolismo , Ativação de Macrófagos/efeitos dos fármacos , Macrófagos Alveolares/efeitos dos fármacos , Macrófagos Alveolares/fisiologia , Masculino , Fenótipo , Receptores Imunológicos/metabolismo , Testes de Função Respiratória
8.
Pediatr Pulmonol ; 46(2): 111-8, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20963840

RESUMO

OBJECTIVE: Since preventive therapies for bronchopulmonary dysplasia (BPD) are limited we treated preterm infants with azithromycin to decrease the incidence of BPD. METHODS: Infants less than 1,250 g birth weight were randomized to azithromycin or placebo within 12 hr of beginning mechanical ventilation and within 72 hr of birth. The treatment group received azithromycin 10 mg/kg/day for 7 days followed by 5 mg/kg/day for a maximum of 6 weeks. Aspirates were collected during the study to assay for Ureaplasma. The primary endpoints were incidence of BPD or mortality. (Clinical Trials Identifier: NCT00319956.) RESULTS: A total of 220 infants were enrolled (n=111 azithromycin, and 109 placebo). Mortality was 18% for the azithromycin group versus 22% for the placebo group (P = 0.45). Incidence of BPD was 76% for the azithromycin group versus 84% for the placebo group (P=0.2). The multiple logistic regression analysis demonstrated an odds ratio of 0.46 decrease in the chance of developing BPD or death for the azithromycin group, but was not statistically significant. The incidence of BPD in the Ureaplasma subgroup was 73% in the azithromycin group versus 94% in the placebo group (P=0.03). Analysis of patients in the Ureaplasma subgroup only, using the exact logistic model demonstrated a decrease in BPD or death in the azithromycin group with an estimated odds ratio of 0.026 (0.001-0.618, 95% confidence interval). CONCLUSIONS: Routine use of azithromycin therapy for the prevention of BPD cannot be recommended. The early treatment of Ureaplasma colonized/infected patients might be beneficial, but a larger multi-centered trial is required to assess this more definitively.


Assuntos
Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Displasia Broncopulmonar/prevenção & controle , Recém-Nascido Prematuro , Displasia Broncopulmonar/mortalidade , Método Duplo-Cego , Feminino , Humanos , Incidência , Recém-Nascido , Recém-Nascido de muito Baixo Peso , Masculino , Respiração Artificial , Ureaplasma/isolamento & purificação , Infecções por Ureaplasma/diagnóstico , Infecções por Ureaplasma/tratamento farmacológico , Infecções por Ureaplasma/mortalidade
9.
J Cyst Fibros ; 9(5): 314-22, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20570573

RESUMO

BACKGROUND: Chronic airway inflammation characterizes patients with cystic fibrosis (CF). The role of alternative macrophage activation in this disease course is unknown. OBJECTIVE: We evaluated markers of alternative and classical macrophage activation in the lungs of patients with CF and evaluated these characteristics in the context of Pseudomonas aeruginosa (PA) infection, immunomodulatory drug therapy and pulmonary function. METHODS: Bronchoalveolar lavage or spontaneously expectorated sputum samples were collected from 48 CF patients. Clinical data were related to macrophage surface expression of mannose receptor (MR) (up-regulated in alternatively activated macrophages) and TLR4 (up-regulated in classically activated macrophages). Also, the activity of the alternatively activated macrophage effector molecule arginase was compared among patient groups, and pro- and anti-inflammatory cytokines produced by alternatively and classically activated macrophages were measured. RESULTS: There were significant differences between PA-infected and -uninfected patients in several clinical measurements. PA-infected patients exhibited increased use of azithromycin, up-regulation of MR on CD11b+ cells and increased arginase activity in their lung samples, and had a strong inverse relationship between MR and arginase activity to FEV(1). Upon further analysis, PA-infected patients who were treated with azithromycin had the highest arginase activity and the highest number of macrophages that were MR+TLR4-, and both of these markers were inversely related to the FEV(1). CONCLUSIONS: Our findings suggest an increase in both MR and arginase expression as pulmonary function declines in PA-infected patients with CF. These markers of an alternatively activated macrophage phenotype give cause for future study to define the function of macrophage activation states in the CF lung.


Assuntos
Fibrose Cística/imunologia , Ativação de Macrófagos , Adolescente , Adulto , Antibacterianos/uso terapêutico , Arginase/metabolismo , Azitromicina/uso terapêutico , Biomarcadores/sangue , Contagem de Células , Criança , Pré-Escolar , Fibrose Cística/microbiologia , Fibrose Cística/patologia , Fibrose Cística/fisiopatologia , Citocinas/metabolismo , Feminino , Volume Expiratório Forçado , Humanos , Lactente , Lectinas Tipo C/metabolismo , Macrófagos/patologia , Masculino , Receptor de Manose , Lectinas de Ligação a Manose/metabolismo , Pessoa de Meia-Idade , Fenótipo , Infecções por Pseudomonas/complicações , Infecções por Pseudomonas/tratamento farmacológico , Infecções por Pseudomonas/enzimologia , Receptores de Superfície Celular/metabolismo , Esteroides/uso terapêutico , Regulação para Cima , Adulto Jovem
10.
Am J Health Syst Pharm ; 67(9): 737-40, 2010 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-20410549

RESUMO

PURPOSE: The successful use of inhaled morphine to relieve dyspnea in a patient with end-stage cystic fibrosis (CF) lung disease is described. SUMMARY: A 48-year-old man with CF was hospitalized for a pulmonary exacerbation caused by infection with Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA). His medical history included long-standing depression, chronic pain, spinal stenosis, benign prostatic hypertrophy, iron-deficiency anemia, and colectomy. Over the two previous years, his chronic pain had progressively worsened, and he had developed narcotic dependency. The etiology of his pain was unclear. During this time, his pulmonary status had slowly deteriorated due to chronic infection with P. aeruginosa and MRSA. As his lung function had deteriorated, he and his family had declined consideration for lung transplantation and requested no heroic interventions when death was imminent. His medications at time of admission included supplemental oxygen, dornase alfa, ipratropium bromide, and albuterol. The opioids used by the patient at the time of admission included oral methadone, oral oxycodone, transdermal fentanyl, and oral morphine sulfate. Upon admission with this pulmonary exacerbation, the patient was started on antibiotics. His pain was eventually controlled with i.v. methadone and ketamine, but his dyspnea continued. Inhaled morphine sulfate 2 mg in 5 mL of 0.9% sodium chloride injection was started and administered every four hours. Clinically significant improvements in the patient's dyspnea, measured using a modified Borg score, were observed with subsequent doses. His dyspnea remained well controlled until his death two days later. CONCLUSION: Inhaled morphine was effective in relieving dyspnea in a patient with end-stage CF lung disease.


Assuntos
Fibrose Cística/complicações , Dispneia/tratamento farmacológico , Morfina/administração & dosagem , Morfina/farmacologia , Entorpecentes/administração & dosagem , Administração por Inalação , Dispneia/etiologia , Humanos , Masculino , Staphylococcus aureus Resistente à Meticilina , Pessoa de Meia-Idade , Entorpecentes/farmacologia , Avaliação de Resultados em Cuidados de Saúde , Infecções por Pseudomonas/complicações , Infecções Estafilocócicas/complicações , Doente Terminal
11.
Pediatr Pulmonol ; 44(6): 619-21, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19434691

RESUMO

Inquilinus limosus is a alpha-proteobacterium that has been recently isolate in the airways of cystic fibrosis (CF) patients. We report the isolation of a mucoid strain of I. limosus from the sputum of a 20-year-old male patient with CF over 1 year that was associated with the clinical, spirometric, and radiographic decline in a previously healthy patient.


Assuntos
Fibrose Cística/microbiologia , Infecções por Bactérias Gram-Negativas/microbiologia , Pneumonia Bacteriana/microbiologia , Rhodospirillaceae/isolamento & purificação , Humanos , Masculino , Testes de Sensibilidade Microbiana , Rhodospirillaceae/efeitos dos fármacos , Adulto Jovem
12.
Heart Fail Rev ; 14(3): 171-82, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18758945

RESUMO

Insomnia is highly prevalent in patients with chronic disease including chronic heart failure (CHF) and is a significant contributing factor to fatigue and poor quality of life. The pathophysiology of CHF often leads to fatigue, due to nocturnal symptoms causing sleep disruption, including cough, orthopnea, paroxysmal nocturnal dyspnea, and nocturia. Inadequate cardiac function may lead to hypoxemia or poor perfusion of the cerebrum, skeletal muscle, or visceral body organs, which result in organ dysfunction or failure and may contribute to fatigue. Sleep disturbances negatively affect all dimensions of quality of life and is related to increased risk of comorbidities, including depression. This article reviews insomnia in CHF, cardiac medication side-effects related to sleep disturbances, and treatment options.


Assuntos
Fadiga/etiologia , Insuficiência Cardíaca/complicações , Humanos , Hipnóticos e Sedativos , Kentucky/epidemiologia , Qualidade de Vida , Distúrbios do Início e da Manutenção do Sono/complicações , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Distúrbios do Início e da Manutenção do Sono/epidemiologia , Transtornos do Sono-Vigília/complicações , Estados Unidos/epidemiologia
13.
Pediatr Pulmonol ; 43(5): 511-3, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18383117

RESUMO

Intravenous continuous infusion of betalactam (CIBL) antibiotic and high dose extended interval (HDEI) aminoglycoside therapy theoretically maximize bacterial killing in treatment of Pseudomonas aeruginosa (PsA) in pulmonary exacerbations of cystic fibrosis (CF). We present the case of a 3-month-old female infant with CF who failed outpatient eradication of PsA with subsequent eradication using intravenous CIBL antibiotic and HDEI aminoglycoside therapy. This antibiotic combination should be considered in order to optimize pharmacodynamics for PsA eradication in CF patients before development of chronic colonization.


Assuntos
Aminoglicosídeos/uso terapêutico , Antibacterianos/uso terapêutico , Fibrose Cística/microbiologia , Infecções por Pseudomonas/tratamento farmacológico , Pseudomonas aeruginosa/efeitos dos fármacos , beta-Lactamas/uso terapêutico , Aminoglicosídeos/administração & dosagem , Antibacterianos/administração & dosagem , Área Sob a Curva , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Feminino , Humanos , Lactente , Infusões Intravenosas , Pacientes Internados , Pacientes Ambulatoriais , Pseudomonas aeruginosa/isolamento & purificação , Falha de Tratamento , Resultado do Tratamento , beta-Lactamas/administração & dosagem
14.
J Antimicrob Chemother ; 61(3): 554-60, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18230686

RESUMO

OBJECTIVES: To investigate the in vitro effects of azithromycin on macrophage phenotype. Utilizing a mouse macrophage cell line (J774), we examined the effect of azithromycin on the properties that define classical macrophage activation (M1) and alternative macrophage activation (M2). METHODS: J774 cells were cultured in the presence of azithromycin and stimulated with classical activation [interferon-gamma (IFNgamma)] and alternative activation [interleukin (IL)-4 and IL-13] cytokines along with lipopolysaccharide (LPS). Macrophages were analysed for inflammatory cytokine production, surface receptor expression, inducible nitric oxide synthase (iNOS) protein expression and arginase activity. RESULTS: Azithromycin altered the overall macrophage phenotype. Azithromycin-treated J774 macrophages demonstrated a significantly reduced production of the pro-inflammatory cytokines IL-12 and IL-6, increased production of the anti-inflammatory cytokine IL-10 and decreased the ratio of IL-12 to IL-10 by 60%. Receptor expression indicative of the M2 phenotype (mannose receptor and CD23) was increased, and receptor expression typically up-regulated in M1 cells (CCR7) was inhibited. The presence of azithromycin increased arginase (M2 effector molecule) activity 10-fold in cells stimulated with IFNgamma and LPS, and iNOS protein (M1 effector molecule) concentrations were attenuated by the drug. CONCLUSIONS: These data provide evidence that azithromycin affects the inflammatory process at the level of the macrophage and shifts macrophage polarization towards the alternatively activated phenotype. This recently defined M2 phenotype has been described in conditions in which pulmonary inflammation and fibrosis are major determinants of clinical outcome, but the concept of antibiotics altering macrophage phenotype has not yet been critically evaluated.


Assuntos
Azitromicina/farmacologia , Imunofenotipagem , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Animais , Linhagem Celular , Linhagem Celular Transformada , Citocinas/biossíntese , Citocinas/genética , Macrófagos/classificação , Macrófagos/metabolismo , Camundongos , Camundongos Endogâmicos BALB C
15.
Respir Res ; 8: 41, 2007 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-17550598

RESUMO

BACKGROUND: Azithromycin reduces the severity of illness in patients with inflammatory lung disease such as cystic fibrosis and diffuse panbronchiolitis. Bronchopulmonary dysplasia (BPD) is a pulmonary disorder which causes significant morbidity and mortality in premature infants. BPD is pathologically characterized by inflammation, fibrosis and impaired alveolar development. The purpose of this study was to obtain pilot data on the effectiveness and safety of prophylactic azithromycin in reducing the incidence and severity of BPD in an extremely low birth weight (< or = 1000 grams) population. METHODS: Infants < or = 1000 g birth weight admitted to the University of Kentucky Neonatal Intensive Care Unit (level III, regional referral center) from 9/1/02-6/30/03 were eligible for this pilot study. The pilot study was double-blinded, randomized, and placebo-controlled. Infants were randomized to treatment or placebo within 12 hours of beginning mechanical ventilation (IMV) and within 72 hours of birth. The treatment group received azithromycin 10 mg/kg/day for 7 days followed by 5 mg/kg/day for the duration of the study. Azithromycin or placebo was continued until the infant no longer required IMV or supplemental oxygen, to a maximum of 6 weeks. Primary endpoints were incidence of BPD as defined by oxygen requirement at 36 weeks gestation, post-natal steroid use, days of IMV, and mortality. Data was analyzed by intention to treat using Chi-square and ANOVA. RESULTS: A total of 43 extremely premature infants were enrolled in this pilot study. Mean gestational age and birth weight were similar between groups. Mortality, incidence of BPD, days of IMV, and other morbidities were not significantly different between groups. Post-natal steroid use was significantly less in the treatment group [31% (6/19)] vs. placebo group [62% (10/16)] (p = 0.05). Duration of mechanical ventilation was significantly less in treatment survivors, with a median of 13 days (1-47 days) vs. 35 days (1-112 days)(p = 0.02). CONCLUSION: Our study suggests that azithromycin prophylaxis in extremely low birth weight infants may effectively reduce post-natal steroid use for infants. Further studies are needed to assess the effects of azithromycin on the incidence of BPD and possible less common side effects, before any recommendations regarding routine clinical use can be made.


Assuntos
Azitromicina/administração & dosagem , Displasia Broncopulmonar/prevenção & controle , Recém-Nascido de Peso Extremamente Baixo ao Nascer , Antibacterianos/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Método Duplo-Cego , Feminino , Humanos , Recém-Nascido , Masculino , Projetos Piloto , Efeito Placebo , Resultado do Tratamento
16.
J Infect ; 54(4): e211-3, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17207858

RESUMO

We present a case of drug-induced eosinophilic pneumonia resulting from intravenous daptomycin being used as therapy for recurrent methicillin-sensitive Staphlococcus aureus endocarditis. The patient developed hypoxic respiratory failure requiring intubation and mechanical ventilation. Daptomycin therapy was discontinued immediately, and the patient improved significantly after the administration of intravenous corticosteroids allowing for extubation 3 days later.


Assuntos
Antibacterianos/efeitos adversos , Daptomicina/efeitos adversos , Endocardite Bacteriana/tratamento farmacológico , Endocardite Bacteriana/microbiologia , Eosinofilia Pulmonar/induzido quimicamente , Staphylococcus aureus/efeitos dos fármacos , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Daptomicina/administração & dosagem , Daptomicina/uso terapêutico , Humanos , Masculino , Meticilina/farmacologia , Pessoa de Meia-Idade , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...